Gynecare TVT Exact Continence System
DeviceParticipants will have placement of Gynecare TVT Exact sling.
Other names: Midurethral sling
NCT Number: NCT04985799
To assess to the non-inferiority of the retropubic Neomedic Knotless Incontinence Mesh (KIM) sling compared to the Gynecare Tension-free Vaginal Tape (TVT) Exact sling.
Participants: Women 21 years or older with a diagnosis of stress urinary incontinence (SUI) or mixed urinary incontinence (MUI) with objective evidence of SUI planning surgery for stress urinary incontinence.
Procedures (methods): Patients will be randomized to receive either the Gynecare TVT Exact sling or the retropubic Neomedic KIM sling. Patients will be followed for 1 year postoperatively.
Looking for future studies?
Notify Me21 year and older
Female
Interventional
Not applicable
UNC Hospitals Hillsborough Campus, Hillsborough, North Carolina, United States
Midurethral slings (MUS) are recognized as a minimally invasive treatment of SUI. The retropubic route of MUS placement has a cure rate of 89.1% with long term subjective cure rates ranging from 51-88%. The Neomedic Knotless Incontinence Mesh (KIM) sling is a tension-free macroporous monofilament polypropylene knotless mesh designed to be resistant to elongation and deformation over time. The KIM sling also offers a reusable trocar, which results in less waste and cost- savings. KIM sling trocars are available for the retropubic route or trans-obturator (TOT) route.
While studies have been performed comparing the TOT approach of the KIM sling to other slings, no studies have been performed to date with the retropubic (RP) approach. The RP and TOT approaches to MUS have been shown to be equivalent in the treatment of SUI. Since the same mesh material of the KIM sling is used for both the TOT and RP approach, it can be hypothesis that the RP route would show similar treatment success rates.
A type 1 macroporous (> 75um) polypropylene mesh is the most appropriate material for vaginal implantation. However, literature has suggested that the design and weave of synthetic mesh material can also have a significant effect on efficacy and safety; therefore, the novel design of the KIM may be beneficial to reduce complications. If there is similar efficacy with the RP approach of the KIM sling to the TVT Exact, there will be benefit of reduced costs and the potential for less complications. With this study, the objective is to show non-inferiority of the KIM sling to the Gynecare TVT Exact.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will have placement of Gynecare TVT Exact sling.
Other names: Midurethral sling
Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
Other names: Midurethral sling
Time frame: 6 weeks after surgery
Treatment success is defined by a composite outcome of 1) response of No or "no bother" to question #3 on urogenital distress inventory-6 (UDI-6) validated questionnaire AND no retreatment of stress incontinence.
Time frame: up to 1 year
Treatment success is defined by a composite outcome of 1) response of No or "no bother" to question #3 on urogenital distress inventory-6 (UDI-6) validated questionnaire AND no retreatment of stress incontinence.
Time frame: up to 1 year
Reoperation for mesh complications or urinary retention thru 1 year after initial sling surgery
Time frame: up to 1 year after surgery
Sling mesh exposure identified on examination thru 1 year after surgery
University of North Carolina, Chapel Hill
Other
A Randomized Controlled Trial Comparing Retropubic KIM Sling to TVT Exact Midurethral Sling
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07668128
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
New Taipei City, Banqiao Dist, Taiwan
View Trial DetailsNCT03913845
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Bethel Park, Pennsylvania, United States
View Trial DetailsNCT02785016
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Frauenfeld, Thurgau, Switzerland
View Trial DetailsNCT07095283
Behavior, Female Urogenital Diseases
Elche, Alicante, Spain
View Trial Details